Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel
Crossref DOI link: https://doi.org/10.1007/s00280-014-2572-z
Published Online: 2014-10-12
Published Print: 2014-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Sarantopoulos, John
Mita, Alain C.
Wade, James L.
Morris, John C.
Rixe, Olivier
Mita, Monica M.
Dedieu, Jean-François
Wack, Claudine
Kassalow, Laurent
Craig Lockhart, A.
Text and Data Mining valid from 2014-10-12